Citi analyst Samantha Semenkow raised the firm’s price target on Argenx (ARGX) to $803 from $796 and keeps a Buy rating on the shares. While the company’s Q1 Vyvgart revenues of $790M were in-line with consensus, the shares closed down 9% with the print being viewed as light in comparison to several recent quarters with significant double-digit quarter-over-quarter growth, the analyst tells investors in a research note. However, the firm anticipates Q2 revenue will benefit from the initial pre-filled syringe launch and removal of seasonality headwinds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx Reports Strong Q1 2025 Financial Performance
- Argenx Se: Strong Sales and Financial Performance Reinforce Buy Rating Amid Stock Selloff
- Strong Buy Rating for Argenx Amid Vyvgart’s Outperformance and Promising Pipeline
- Argenx SE Reports Strong Q1 2025 Financial Results and Advances Vision 2030
- Argenx reports Q1 EPS $2.58, consensus $2.75